Exxonmobil Investment Management Inc. TX Sells 5,828 Shares of Vertex Pharmaceuticals Incorporated (VRTX)

Exxonmobil Investment Management Inc. TX lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,213 shares of the pharmaceutical company’s stock after selling 5,828 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Vertex Pharmaceuticals were worth $6,026,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. raised its stake in shares of Vertex Pharmaceuticals by 15.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after purchasing an additional 132 shares during the last quarter. FNY Partners Fund LP raised its stake in shares of Vertex Pharmaceuticals by 900.0% in the second quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after purchasing an additional 900 shares during the last quarter. Smithfield Trust Co. purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth approximately $135,000. FNY Managed Accounts LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth approximately $162,000. Finally, Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth approximately $198,000. Institutional investors and hedge funds own 93.09% of the company’s stock.

VRTX has been the subject of several analyst reports. DA Davidson started coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. BTIG Research started coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 price target for the company. BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. Finally, Maxim Group reaffirmed a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $175.89.

In other news, Director Sangeeta N. Bhatia sold 10,753 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $156.00, for a total value of $1,677,468.00. Following the completion of the transaction, the director now directly owns 14,706 shares of the company’s stock, valued at $2,294,136. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 3,438 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $151.80, for a total value of $521,888.40. Following the completion of the transaction, the chief marketing officer now directly owns 57,862 shares of the company’s stock, valued at $8,783,451.60. The disclosure for this sale can be found here. Insiders sold 356,339 shares of company stock valued at $51,479,669 over the last ninety days. Corporate insiders own 1.80% of the company’s stock.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $156.01 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. Vertex Pharmaceuticals Incorporated has a 52-week low of $79.78 and a 52-week high of $167.85. The stock has a market capitalization of $39,460.00, a price-to-earnings ratio of 200.01, a price-to-earnings-growth ratio of 1.84 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The firm had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. During the same period last year, the company earned $0.16 earnings per share. The business’s revenue for the quarter was up 39.7% on a year-over-year basis. equities analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Exxonmobil Investment Management Inc. TX Sells 5,828 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2018/01/10/exxonmobil-investment-management-inc-tx-sells-5828-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit